There are so many moving parts. <br /> <br /> - McCoy consulting firm <br /> - PureMed <br /> - Life Sciences <br /> - RGIN <br /> <br /> Now everyone in RGIN is on PM's board. Nelson runs PM. They have the only FDA APPROVED facility in US. They are the main distributor on LS product. So if falling out with McCoy that's not end of the world at all. They have own producing facility in Alabama. Besides there are many more farms moving to collagen as way more profitable, so LS not only game in town. <br /> <br /> Its about getting financing and into trials. There are many more people involved then just RGIN employees. Its just that stock will get the benefit <br /> <br /> What they were looking to accomplish in 2017: <br /> <br /> Obviously Late: But this next report is VERY IMPORTANT <br /> <br /> <br /> • Secure interim financing to finalize product development needed to support the IND; <br /> <br /> • Complete a second round of financing in order to conduct 10 patient clinical trials with NovaDerm® and finalize required manufacturing engineering runs and validations; <br /> <br /> • Work with Pure Med Farma to finalize Collagen Scaffold Testing Specifications for NovaDerm®; <br /> <br /> • Finalize contracts with the CRO and select the NovaDerm® clinical trial material manufacturer; <br /> <br /> • Retain a Principal lead investigator, medical advisor, surgical trainer and dermopathologist; <br /> <br /> • Select and execute contracts with two clinical study sites; and <br /> <br /> • Perform a successful graft of NovaDerm onto a clinical trial subject.